A matched case control study with propensity score balancing examining the protective effect of paracetamol against parentally reported apnoea in infants

Paul Walsh, Lucas Shanholtzer, Mark Loewen, Kim Trinh, Ben McEnulty, Stephen J. Rothenberg

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Central apnoea occurs in infants and if not detected leads to death. Central apnoea is a prostaglandin E 2 (PGE2) mediated effect that is susceptible to pharmacologic manipulation in animal models. Paracetamol and ibuprofen are centrally and peripherally acting PGE2 inhibitors, respectively. Aim: To determine if infants who had received paracetamol or ibuprofen are relatively protected from apnoea. Methods: We performed a matched case control study using propensity score balancing to adjust for non-random drug assignment. We included infants from prospective studies of central apnoea and bronchiolitis. We matched on age, prematurity and fever to adjust for the infants' underlying risk of apnoea. The primary outcome measure was odds of exposure to paracetamol or ibuprofen by apneic infants compared to their controls. Results: Forty-two apneic and 729 non-apneic infants were identified. Infants with apnoea were younger than those without, median age 6.5 versus 12.2. weeks and were more likely to be premature. These differences were balanced using matching. Differences between those who did and did not receive paracetamol were satisfactorily balanced using the propensity score. Ibuprofen was used too infrequently to analyse it further. In the unadjusted analysis fewer apneic infants had had prior paracetamol use 5/42 (12%) versus 211/729 (29%) or prior ibuprofen use 1/42 (2%) versus 51/729 (7%). In the adjusted analysis paracetamol was protective against apnoea; OR 0.30 (95% CI 0.11, 0.78). Conclusions: Prior paracetamol use was protective against apnoea in infants. We could not demonstrate an effect for ibuprofen.

Original languageEnglish (US)
Pages (from-to)440-446
Number of pages7
JournalResuscitation
Volume83
Issue number4
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

Propensity Score
Apnea
Acetaminophen
Case-Control Studies
Ibuprofen
Central Sleep Apnea
Prostaglandins E
Bronchiolitis
Fever
Animal Models
Outcome Assessment (Health Care)
Prospective Studies

Keywords

  • Apnoea
  • Ibuprofen
  • Paracetamol
  • Prostaglandin E2

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Emergency
  • Emergency Medicine

Cite this

A matched case control study with propensity score balancing examining the protective effect of paracetamol against parentally reported apnoea in infants. / Walsh, Paul; Shanholtzer, Lucas; Loewen, Mark; Trinh, Kim; McEnulty, Ben; Rothenberg, Stephen J.

In: Resuscitation, Vol. 83, No. 4, 04.2012, p. 440-446.

Research output: Contribution to journalArticle

Walsh, Paul ; Shanholtzer, Lucas ; Loewen, Mark ; Trinh, Kim ; McEnulty, Ben ; Rothenberg, Stephen J. / A matched case control study with propensity score balancing examining the protective effect of paracetamol against parentally reported apnoea in infants. In: Resuscitation. 2012 ; Vol. 83, No. 4. pp. 440-446.
@article{04316e193b7046859f4e38cc38a8eee8,
title = "A matched case control study with propensity score balancing examining the protective effect of paracetamol against parentally reported apnoea in infants",
abstract = "Background: Central apnoea occurs in infants and if not detected leads to death. Central apnoea is a prostaglandin E 2 (PGE2) mediated effect that is susceptible to pharmacologic manipulation in animal models. Paracetamol and ibuprofen are centrally and peripherally acting PGE2 inhibitors, respectively. Aim: To determine if infants who had received paracetamol or ibuprofen are relatively protected from apnoea. Methods: We performed a matched case control study using propensity score balancing to adjust for non-random drug assignment. We included infants from prospective studies of central apnoea and bronchiolitis. We matched on age, prematurity and fever to adjust for the infants' underlying risk of apnoea. The primary outcome measure was odds of exposure to paracetamol or ibuprofen by apneic infants compared to their controls. Results: Forty-two apneic and 729 non-apneic infants were identified. Infants with apnoea were younger than those without, median age 6.5 versus 12.2. weeks and were more likely to be premature. These differences were balanced using matching. Differences between those who did and did not receive paracetamol were satisfactorily balanced using the propensity score. Ibuprofen was used too infrequently to analyse it further. In the unadjusted analysis fewer apneic infants had had prior paracetamol use 5/42 (12{\%}) versus 211/729 (29{\%}) or prior ibuprofen use 1/42 (2{\%}) versus 51/729 (7{\%}). In the adjusted analysis paracetamol was protective against apnoea; OR 0.30 (95{\%} CI 0.11, 0.78). Conclusions: Prior paracetamol use was protective against apnoea in infants. We could not demonstrate an effect for ibuprofen.",
keywords = "Apnoea, Ibuprofen, Paracetamol, Prostaglandin E2",
author = "Paul Walsh and Lucas Shanholtzer and Mark Loewen and Kim Trinh and Ben McEnulty and Rothenberg, {Stephen J.}",
year = "2012",
month = "4",
doi = "10.1016/j.resuscitation.2011.12.006",
language = "English (US)",
volume = "83",
pages = "440--446",
journal = "Resuscitation",
issn = "0300-9572",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - A matched case control study with propensity score balancing examining the protective effect of paracetamol against parentally reported apnoea in infants

AU - Walsh, Paul

AU - Shanholtzer, Lucas

AU - Loewen, Mark

AU - Trinh, Kim

AU - McEnulty, Ben

AU - Rothenberg, Stephen J.

PY - 2012/4

Y1 - 2012/4

N2 - Background: Central apnoea occurs in infants and if not detected leads to death. Central apnoea is a prostaglandin E 2 (PGE2) mediated effect that is susceptible to pharmacologic manipulation in animal models. Paracetamol and ibuprofen are centrally and peripherally acting PGE2 inhibitors, respectively. Aim: To determine if infants who had received paracetamol or ibuprofen are relatively protected from apnoea. Methods: We performed a matched case control study using propensity score balancing to adjust for non-random drug assignment. We included infants from prospective studies of central apnoea and bronchiolitis. We matched on age, prematurity and fever to adjust for the infants' underlying risk of apnoea. The primary outcome measure was odds of exposure to paracetamol or ibuprofen by apneic infants compared to their controls. Results: Forty-two apneic and 729 non-apneic infants were identified. Infants with apnoea were younger than those without, median age 6.5 versus 12.2. weeks and were more likely to be premature. These differences were balanced using matching. Differences between those who did and did not receive paracetamol were satisfactorily balanced using the propensity score. Ibuprofen was used too infrequently to analyse it further. In the unadjusted analysis fewer apneic infants had had prior paracetamol use 5/42 (12%) versus 211/729 (29%) or prior ibuprofen use 1/42 (2%) versus 51/729 (7%). In the adjusted analysis paracetamol was protective against apnoea; OR 0.30 (95% CI 0.11, 0.78). Conclusions: Prior paracetamol use was protective against apnoea in infants. We could not demonstrate an effect for ibuprofen.

AB - Background: Central apnoea occurs in infants and if not detected leads to death. Central apnoea is a prostaglandin E 2 (PGE2) mediated effect that is susceptible to pharmacologic manipulation in animal models. Paracetamol and ibuprofen are centrally and peripherally acting PGE2 inhibitors, respectively. Aim: To determine if infants who had received paracetamol or ibuprofen are relatively protected from apnoea. Methods: We performed a matched case control study using propensity score balancing to adjust for non-random drug assignment. We included infants from prospective studies of central apnoea and bronchiolitis. We matched on age, prematurity and fever to adjust for the infants' underlying risk of apnoea. The primary outcome measure was odds of exposure to paracetamol or ibuprofen by apneic infants compared to their controls. Results: Forty-two apneic and 729 non-apneic infants were identified. Infants with apnoea were younger than those without, median age 6.5 versus 12.2. weeks and were more likely to be premature. These differences were balanced using matching. Differences between those who did and did not receive paracetamol were satisfactorily balanced using the propensity score. Ibuprofen was used too infrequently to analyse it further. In the unadjusted analysis fewer apneic infants had had prior paracetamol use 5/42 (12%) versus 211/729 (29%) or prior ibuprofen use 1/42 (2%) versus 51/729 (7%). In the adjusted analysis paracetamol was protective against apnoea; OR 0.30 (95% CI 0.11, 0.78). Conclusions: Prior paracetamol use was protective against apnoea in infants. We could not demonstrate an effect for ibuprofen.

KW - Apnoea

KW - Ibuprofen

KW - Paracetamol

KW - Prostaglandin E2

UR - http://www.scopus.com/inward/record.url?scp=84858032499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858032499&partnerID=8YFLogxK

U2 - 10.1016/j.resuscitation.2011.12.006

DO - 10.1016/j.resuscitation.2011.12.006

M3 - Article

C2 - 22178799

AN - SCOPUS:84858032499

VL - 83

SP - 440

EP - 446

JO - Resuscitation

JF - Resuscitation

SN - 0300-9572

IS - 4

ER -